Light-activated disinfectant technology using polyoxometalates (POMs) that absorb visible and near-UV light to produce antimicrobial and antiviral effects. These benign, tunable, inexpensive early-transition-metal oxygen anion clusters can serve as standalone disinfectants or enhance the efficacy of existing disinfectant formulations for household and commercial use.
This technology leverages polyoxometalates (POMs)—clusters of oxygen anions built from inexpensive, benign early transition metals such as tungsten, molybdenum, niobium, and vanadium—as visible-light-activated photocatalytic disinfectants. POMs absorb visible and near-UV light to form excited states that directly attack microbes, while the resulting photoreduced POMs react with ambient oxygen to generate reactive oxygen species (ROS) that further enhance antimicrobial and virucidal activity. The technology is designed both as a standalone light-activated disinfectant and as an additive that boosts the performance of existing disinfectant formulations. Because POMs have been extensively evaluated for toxicity in cell culture and animal studies and found to be very benign, they offer a safer profile than many conventional chemical disinfectants.
The underlying photocatalytic chemistry has been validated in closely related antimicrobial and antiviral applications through prior agency and corporate-funded research, with all key processes confirmed. The specific application to household disinfection has not yet been evaluated and represents the next stage of development. Planned validation includes evaluating lead POMs for rapid, ambient-conditions disinfection of common household microbes and biohazards, demonstrating compatibility with current disinfectants, and confirming that POM additives improve the performance of existing formulations. Optimization of light absorption, quantum yields, and excited-state lifetimes is ongoing. The technology is at an early-to-mid stage of development, ready for targeted validation studies and partnerships aimed at translating the chemistry into commercial disinfection products.
Emory University is a comprehensive private research university in Atlanta, anchored by a major academic health center and a mid-sized, research-active faculty. Integration with its academic health system provides direct access to patients, clinicians, and real-world data, enabling rapid clinical translation and large, multisite trials. A hospital-embedded innovation hub and proximity to the CDC and Atlanta’s corporate ecosystem create frequent pathways for co-development, testing, and deployment with industry partners; a long-standing partnership with a neighboring engineering powerhouse broadens prototyping and scale-up options. Research is supported by competitive federal funding, including the National Institutes of Health and the National Science Foundation. A dedicated technology transfer office supports IP strategy, licensing, startup formation, and streamlined industry agreements.